BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asahina Y, Izumi N, Hiromitsu K, Kurosaki M, Koike K, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H, Hayashi N, Hiramatsu N, Yotsuyanagi H. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. Hepatol Res 2015;46:129-65. [DOI: 10.1111/hepr.12645] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Reference Citation Analysis]
2 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 2020;50:791-816. [PMID: 32343477 DOI: 10.1111/hepr.13503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
3 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Ohfuji S, Matsuura T, Tamori A, Kubo S, Sasaki S, Kondo K, Ito K, Fukushima W. Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan. Dig Dis Sci 2021;66:2118-28. [PMID: 32720018 DOI: 10.1007/s10620-020-06475-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat 2018;25:945-51. [DOI: 10.1111/jvh.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
6 Hirayama T, Ikegami T, Honda A, Miyazaki T, Yara SI, Kohjima M, Nakamuta M, Matsuzaki Y. Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Intern Med 2018;57:1219-27. [PMID: 29279486 DOI: 10.2169/internalmedicine.9479-17] [Reference Citation Analysis]
7 Kobayashi H, Joshita S, Akahane Y, Matsuzaki K, Yamada H, Aomura D, Joshita N, Midorikawa H, Suyama K, Ota M, Wakabayashi SI, Yamashita Y, Sugiura A, Yamazaki T, Misawa H, Umemura T. Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project. PLoS One 2021;16:e0256711. [PMID: 34437651 DOI: 10.1371/journal.pone.0256711] [Reference Citation Analysis]
8 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
9 Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU. The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver Int. 2017;37:159-172. [PMID: 27748564 DOI: 10.1111/liv.13272] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
10 Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Ishii A, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis. Medicine (Baltimore) 2017;96:e5800. [PMID: 28099336 DOI: 10.1097/MD.0000000000005800] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
11 Hsieh YC, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin SM, Tai DI, Lin CY, Sheen IS. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLoS One 2018;13:e0202777. [PMID: 30138456 DOI: 10.1371/journal.pone.0202777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; for the NORTE Study Group. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study: FLV add-on SMV/Peg-IFN/RBV therapy. Hepatol Res 2018;48:E146-54. [DOI: 10.1111/hepr.12938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Sugiura A, Joshita S, Yamashita Y, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Nakano Y, Usuda S, Kiyosawa K, Tanaka E, Umemura T. Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. Biomedicines 2020;8:E74. [PMID: 32260271 DOI: 10.3390/biomedicines8040074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatol Res. 2018;48:529-538. [PMID: 29316051 DOI: 10.1111/hepr.13056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
15 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62:pii: e02217-17. [PMID: 29180522 DOI: 10.1128/aac.02217-17:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Hagiwara H, Ito Y, Ohta T, Nozaki Y, Iwamoto T, Hosui A, Hiramatsu N, Tahata Y, Sakamori R, Hikita H, Hayashi N. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct‐acting antiviral agents among the working population in Japan. JGH Open. [DOI: 10.1002/jgh3.12745] [Reference Citation Analysis]
17 Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int 2018;12:133-42. [PMID: 29600429 DOI: 10.1007/s12072-018-9859-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
18 Nagai K, Ide K, Kawasaki Y, Tanaka-Mizuno S, Seto K, Iwane S, Eguchi Y, Kawakami K. Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan. Hepatol Res 2020;50:542-56. [PMID: 31899841 DOI: 10.1111/hepr.13478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. J Clin Pharmacol 2020;60:331-9. [PMID: 31515816 DOI: 10.1002/jcph.1524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C: Ombitasvir/paritaprevir/ritonavir for dialysis patients. Hepatol Res 2017;47:1429-37. [DOI: 10.1111/hepr.12910] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
21 Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH Open 2018;2:300-6. [PMID: 30619941 DOI: 10.1002/jgh3.12088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Morishita A, Ogawa C, Moriya A, Tani J, Yoneyama H, Fujita K, Oryu M, Senoo T, Takaguchi K, Masaki T. Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. Hepatol Res 2020;50:557-64. [PMID: 31883211 DOI: 10.1111/hepr.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, Itoh Y, Mochida S, Toyoda H, Yoshiji H, Takaki S, Yatsuzuka N, Yodoya E, Iwasa T, Fujimoto G, Robertson MN, Black S, Caro L, Wahl J. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol 2017;52:520-33. [PMID: 27873094 DOI: 10.1007/s00535-016-1285-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
25 Yamashita Y, Joshita S, Sugiura A, Yamazaki T, Kobayashi H, Wakabayashi SI, Yamada Y, Shibata S, Kunimoto H, Iwadare T, Matsumura M, Miyabayashi C, Okumura T, Ozawa S, Nozawa Y, Kobayashi N, Komatsu M, Fujimori N, Saito H, Umemura T. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Hepatol Res 2021. [PMID: 34216422 DOI: 10.1111/hepr.13689] [Reference Citation Analysis]
26 Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:1602-1609. [PMID: 31975438 DOI: 10.1111/jgh.14991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N. Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. J Clin Transl Hepatol 2016;4:320-7. [PMID: 28097101 DOI: 10.14218/JCTH.2016.00032] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
28 Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, Seike M, Takei Y, Kato K, Alves K, Burroughs M, Redman R, Pugatch DL, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557-565. [PMID: 28948366 DOI: 10.1007/s00535-017-1391-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 16.2] [Reference Citation Analysis]
29 Takeuchi S, Takamura M, Yoshida T, Takahashi K, Hayashi K, Hashimoto S, Yamagiwa S, Tasaki M, Nakagawa Y, Saito K, Tanabe Y, Tomita Y, Terai S. Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels. Transplant Proc 2018;50:884-6. [PMID: 29661458 DOI: 10.1016/j.transproceed.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Tanaka Y, Tateishi R, Koike K. Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature. Clin J Gastroenterol 2019;12:588-91. [PMID: 31134448 DOI: 10.1007/s12328-019-00997-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Virabhak S, Yasui K, Yamazaki K, Johnson S, Mitchell D, Yuen C, Samp JC, Igarashi A. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016;19:1144-56. [PMID: 27348464 DOI: 10.1080/13696998.2016.1206908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
33 Tahata Y, Sakamori R, Urabe A, Morishita N, Yamada R, Yakushijin T, Hiramatsu N, Doi Y, Kaneko A, Hagiwara H, Yamada Y, Hijioka T, Inada M, Tamura S, Imai Y, Furuta K, Kodama T, Hikita H, Tatsumi T, Takehara T. Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. Hepatol Commun 2018;2:884-92. [PMID: 30094400 DOI: 10.1002/hep4.1206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. Sci Rep 2019;9:5722. [PMID: 30952914 DOI: 10.1038/s41598-019-42114-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
35 Asahina Y, Itoh Y, Ueno Y, Matsuzaki Y, Takikawa Y, Yatsuhashi H, Genda T, Ikeda F, Matsuda T, Dvory-Sobol H, Jiang D, Massetto B, Osinusi AO, Brainard DM, McHutchison JG, Kawada N, Enomoto N. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018;38:1552-1561. [PMID: 29297980 DOI: 10.1111/liv.13685] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
36 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62. [PMID: 29180522 DOI: 10.1128/aac.02217-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
37 Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Kato K, Okubo T, Arai T, Itokawa N, Iio E, Tanaka Y, Iwakiri K. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis. 2017;49:1029-1035. [PMID: 28499694 DOI: 10.1016/j.dld.2017.04.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
38 Kumada H, Mochida S, Nakamuta M, Suzuki F, Yagi T, Takasaki R, Okai M, Kamiya N, Okada Y, Hirota S, Orihashi M, Ochi M, Chayama K. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res 2018;48:184-92. [PMID: 28497489 DOI: 10.1111/hepr.12914] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Sohda T, Yokoyama K, Yamauchi E, Anan A, Tanaka T, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S. Efficacy of sofosbuvir and ledipasvir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res 2017;47:1494. [PMID: 28258608 DOI: 10.1111/hepr.12889] [Reference Citation Analysis]
40 Kwon JE, Lee Y, Kang J, Bai Y, Jeong YJ, Baek N, Seo Y, Kang SC. Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture. Bioorganic Chemistry 2019;93:103320. [DOI: 10.1016/j.bioorg.2019.103320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Joshita S, Yamashita Y, Okamoto T, Usami Y, Sugiura A, Yamazaki T, Kakino A, Ota M, Sawamura T, Umemura T. Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct-acting antivirals. Hepatol Res 2021;51:758-66. [PMID: 33982310 DOI: 10.1111/hepr.13666] [Reference Citation Analysis]
43 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
44 Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther 2019;49:1230-41. [DOI: 10.1111/apt.15218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
45 Go H, Tanaka M, Yamamoto-Mitani N, Suzuki M, Kawakami A, Masaki N, Shimada M. Medication Adherence Among Patients With Chronic Hepatitis Receiving Antiviral Treatment. Gastroenterol Nurs 2019;42:140-9. [PMID: 30946301 DOI: 10.1097/SGA.0000000000000363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H. Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. Hepatol Res 2018;48:E78-86. [PMID: 28643404 DOI: 10.1111/hepr.12929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
47 Kwon JH, Yoo SH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee SW, Lee HL, Han NI, Kim SH, Song MJ, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. J Med Virol 2019;91:1104-11. [PMID: 30695109 DOI: 10.1002/jmv.25412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]